Baidu
map

心血管

订阅

MedSci主页 / 所有栏目 / 心血管

Heart：β阻滞剂和联用他汀改善急性心梗远期生存率更佳

2013-07-30 高晓方 译 cmt

β阻滞剂他汀AMI
关注

澳大利亚一项研究表明，出院后联合应用β阻滞剂和他汀类药物与急性心肌梗死（AMI）后远期生存率最高具有相关性，尤其是在男性患者中。论文于7月25日在线发表于《心脏》（Heart）。 此项基于人群的纵向队列研究共纳入9580例因首次AMI而住院的患者。主要转归指标为首次AMI后11年内由登记资料确认的至全因死亡时间。以出院后28天内应用的心血管药物作为主要暴露分类指标。 结果显示，在1年随访期间共

澳大利亚一项研究表明，出院后联合应用β阻滞剂和他汀类药物与急性心肌梗死（AMI）后远期生存率最高具有相关性，尤其是在男性患者中。论文于7月25日在线发表于《心脏》（Heart）。

此项基于人群的纵向队列研究共纳入9580例因首次AMI而住院的患者。主要转归指标为首次AMI后11年内由登记资料确认的至全因死亡时间。以出院后28天内应用的心血管药物作为主要暴露分类指标。

结果显示，在1年随访期间共出现975例死亡，至11年时达到3247例。所有药物组合均可显著降低1年死亡风险，但单独用药无此效应。

至11年时，仅β阻滞剂与他汀类联合（伴或不伴ACE抑制剂/血管紧张素II受体阻断剂[ACEI/ARB]）可显著降低全因死亡风险。在男性中，β阻滞剂和他汀类联合与风险降低最高具有相关性（HR 0.46），女性则从β阻滞剂、他汀类和ACEI/ARB联合中获益最大（HR 0.77）。

Gunnell AS, Einarsdóttir K, Sanfilippo F, Liew D, Holman CD, Briffa T.Improved long-term survival in patients on combination therapies following an incident acute myocardial infarction: a longitudinal population-based study.Heart. 2013 Jul 25. [Epub ahead of print]

PMID:
23886604

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2085693, encodeId=4082208569360, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Mon Mar 10 08:14:00 CST 2014, time=2014-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718221, encodeId=d6671e1822194, content=<a href='/topic/show?id=bf431925337' target=_blank style='color:#2F92EE;'>#β阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19253, encryptionId=bf431925337, topicName=β阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eaba32519184, createdName=zhzhxiang, createdTime=Mon Apr 14 12:14:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256471, encodeId=0cb112564e16e, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308310, encodeId=50c4130831057, content=<a href='/topic/show?id=8323522e503' target=_blank style='color:#2F92EE;'>#急性心梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52275, encryptionId=8323522e503, topicName=急性心梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355784, encodeId=e1011355e845c, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562181, encodeId=cd871562181e8, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5977, encodeId=83d359e751, content=bb 和他汀是改善心梗预后的关键药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1f513086, createdName=freedoc, createdTime=Thu Aug 01 04:08:00 CST 2013, time=2013-08-01, status=1, ipAttribution=)]
    2014-03-10 zhyy88

    #阻滞剂#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2085693, encodeId=4082208569360, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Mon Mar 10 08:14:00 CST 2014, time=2014-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718221, encodeId=d6671e1822194, content=<a href='/topic/show?id=bf431925337' target=_blank style='color:#2F92EE;'>#β阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19253, encryptionId=bf431925337, topicName=β阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eaba32519184, createdName=zhzhxiang, createdTime=Mon Apr 14 12:14:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256471, encodeId=0cb112564e16e, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308310, encodeId=50c4130831057, content=<a href='/topic/show?id=8323522e503' target=_blank style='color:#2F92EE;'>#急性心梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52275, encryptionId=8323522e503, topicName=急性心梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355784, encodeId=e1011355e845c, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562181, encodeId=cd871562181e8, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5977, encodeId=83d359e751, content=bb 和他汀是改善心梗预后的关键药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1f513086, createdName=freedoc, createdTime=Thu Aug 01 04:08:00 CST 2013, time=2013-08-01, status=1, ipAttribution=)]
    2014-04-14 zhzhxiang

    #β阻滞剂#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2085693, encodeId=4082208569360, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Mon Mar 10 08:14:00 CST 2014, time=2014-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718221, encodeId=d6671e1822194, content=<a href='/topic/show?id=bf431925337' target=_blank style='color:#2F92EE;'>#β阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19253, encryptionId=bf431925337, topicName=β阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eaba32519184, createdName=zhzhxiang, createdTime=Mon Apr 14 12:14:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256471, encodeId=0cb112564e16e, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308310, encodeId=50c4130831057, content=<a href='/topic/show?id=8323522e503' target=_blank style='color:#2F92EE;'>#急性心梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52275, encryptionId=8323522e503, topicName=急性心梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355784, encodeId=e1011355e845c, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562181, encodeId=cd871562181e8, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5977, encodeId=83d359e751, content=bb 和他汀是改善心梗预后的关键药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1f513086, createdName=freedoc, createdTime=Thu Aug 01 04:08:00 CST 2013, time=2013-08-01, status=1, ipAttribution=)]
    2013-08-01 guoyibin

    #生存率#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2085693, encodeId=4082208569360, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Mon Mar 10 08:14:00 CST 2014, time=2014-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718221, encodeId=d6671e1822194, content=<a href='/topic/show?id=bf431925337' target=_blank style='color:#2F92EE;'>#β阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19253, encryptionId=bf431925337, topicName=β阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eaba32519184, createdName=zhzhxiang, createdTime=Mon Apr 14 12:14:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256471, encodeId=0cb112564e16e, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308310, encodeId=50c4130831057, content=<a href='/topic/show?id=8323522e503' target=_blank style='color:#2F92EE;'>#急性心梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52275, encryptionId=8323522e503, topicName=急性心梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355784, encodeId=e1011355e845c, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562181, encodeId=cd871562181e8, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5977, encodeId=83d359e751, content=bb 和他汀是改善心梗预后的关键药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1f513086, createdName=freedoc, createdTime=Thu Aug 01 04:08:00 CST 2013, time=2013-08-01, status=1, ipAttribution=)]
    2013-08-01 chenlianhui

    #急性心梗#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2085693, encodeId=4082208569360, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Mon Mar 10 08:14:00 CST 2014, time=2014-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718221, encodeId=d6671e1822194, content=<a href='/topic/show?id=bf431925337' target=_blank style='color:#2F92EE;'>#β阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19253, encryptionId=bf431925337, topicName=β阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eaba32519184, createdName=zhzhxiang, createdTime=Mon Apr 14 12:14:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256471, encodeId=0cb112564e16e, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308310, encodeId=50c4130831057, content=<a href='/topic/show?id=8323522e503' target=_blank style='color:#2F92EE;'>#急性心梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52275, encryptionId=8323522e503, topicName=急性心梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355784, encodeId=e1011355e845c, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562181, encodeId=cd871562181e8, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5977, encodeId=83d359e751, content=bb 和他汀是改善心梗预后的关键药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1f513086, createdName=freedoc, createdTime=Thu Aug 01 04:08:00 CST 2013, time=2013-08-01, status=1, ipAttribution=)]
    2013-08-01 zhaojie88

    #ART#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2085693, encodeId=4082208569360, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Mon Mar 10 08:14:00 CST 2014, time=2014-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718221, encodeId=d6671e1822194, content=<a href='/topic/show?id=bf431925337' target=_blank style='color:#2F92EE;'>#β阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19253, encryptionId=bf431925337, topicName=β阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eaba32519184, createdName=zhzhxiang, createdTime=Mon Apr 14 12:14:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256471, encodeId=0cb112564e16e, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308310, encodeId=50c4130831057, content=<a href='/topic/show?id=8323522e503' target=_blank style='color:#2F92EE;'>#急性心梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52275, encryptionId=8323522e503, topicName=急性心梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355784, encodeId=e1011355e845c, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562181, encodeId=cd871562181e8, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5977, encodeId=83d359e751, content=bb 和他汀是改善心梗预后的关键药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1f513086, createdName=freedoc, createdTime=Thu Aug 01 04:08:00 CST 2013, time=2013-08-01, status=1, ipAttribution=)]
    2013-08-01 slcumt

    #HEART#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2085693, encodeId=4082208569360, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Mon Mar 10 08:14:00 CST 2014, time=2014-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718221, encodeId=d6671e1822194, content=<a href='/topic/show?id=bf431925337' target=_blank style='color:#2F92EE;'>#β阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19253, encryptionId=bf431925337, topicName=β阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eaba32519184, createdName=zhzhxiang, createdTime=Mon Apr 14 12:14:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256471, encodeId=0cb112564e16e, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308310, encodeId=50c4130831057, content=<a href='/topic/show?id=8323522e503' target=_blank style='color:#2F92EE;'>#急性心梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52275, encryptionId=8323522e503, topicName=急性心梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355784, encodeId=e1011355e845c, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562181, encodeId=cd871562181e8, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Aug 01 06:14:00 CST 2013, time=2013-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5977, encodeId=83d359e751, content=bb 和他汀是改善心梗预后的关键药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1f513086, createdName=freedoc, createdTime=Thu Aug 01 04:08:00 CST 2013, time=2013-08-01, status=1, ipAttribution=)]
    2013-08-01 freedoc

    bb 和他汀是改善心梗预后的关键药物

    0

Baidu
map
Baidu
map
Baidu
map